On the contrary, treatment with Vemurafenib reduced the expression of p-p70S6k in control cells but not in cmMSC melanoma cells, confirming the resistance of A375-M6 cmMSC to the BRAF inhibitor (Figure 3(D)). This evidence concerns the gene RPS6KB1 and melanoma.